Immune cells found co-operating to capture and “eat” bacteria
Researchers have identified a spider-like antibacterial mechanism by immune cells that could inspire Staphylococcus aureus treatments.
List view / Grid view
Researchers have identified a spider-like antibacterial mechanism by immune cells that could inspire Staphylococcus aureus treatments.
An NIH team have built a cellular map of chronic multiple sclerosis (MS) lesions to identify cells that drive inflammation and potential therapies.
The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
Study reveals that the HSP27 protein plays a role in regulating blood vessel leakage, providing new targets for drugs against sepsis.
A team of researchers have reversed lung fibrosis in a mouse model, highlighting a new therapeutic target for pulmonary fibrosis.
Researchers have found a vulnerability in a developmental signalling pathway, presenting a target for paediatric low-grade glioma formation.
Researchers have developed a new method that could make enzyme replacement therapy more efficient for Pompe disease treatment.
Scientists used artificial intelligence to identify 17 existing drugs that could kill SARS-CoV-2 in cells, including a dietary supplement.
Researchers have revealed a novel mechanism for platelet activation, suggesting a potential target for antithrombotic therapy.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
Researchers have created a new method to quantify protein droplets involved in neurodegenerative diseases, enhancing the study of treatments.
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.